Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

• Dariush Etemadmoghadam,

  Affiliation Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia

  ⨯
• Joshy George,

  Affiliations Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia, Department of Biochemistry, University of Melbourne, Parkville, Australia

  ⨯
• Prue A. Cowin,

  Affiliation Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia

  ⨯
• Carleen Cullinane,

  Affiliation Translational Research Program, Peter MacCallum Cancer Centre, East Melbourne, Australia

  ⨯
• Maya Kansara,

  Affiliation Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia

  ⨯
• Australian Ovarian Cancer Study Group,
• Kylie L. Gorringe,

  Affiliations Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia, Department of Pathology, University of Melbourne, Parkville, Australia

  ⨯
• Gordon K. Smyth,

  Affiliation Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

  ⨯
• David D. L. Bowtell

  * E-mail: david.bowtell@petermac.org

  Affiliations Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia, Department of Biochemistry, University of Melbourne, Parkville, Australia

  ⨯